Cargando…

Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study

BACKGROUND: The presence of pleural effusion is an independent predictor for poor survival in patients with small‐cell lung cancer (SCLC). The aim of this study was to assess the efficacy and safety of anlotinib in patients with SCLC and pleural effusion. METHODS: This was a randomized, double‐blind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ying, Cheng, Ying, Wang, Qiming, Li, Kai, Shi, Jianhua, Wu, Lin, Han, Baohui, Chen, Gongyan, He, Jianxing, Wang, Jie, Qin, Haifeng, Li, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590889/ https://www.ncbi.nlm.nih.gov/pubmed/34596367 http://dx.doi.org/10.1111/1759-7714.14176

Ejemplares similares

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
por: Cheng, Ying, et al.
Publicado: (2021)

Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
por: Liu, Yang, et al.
Publicado: (2021)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
por: Cheng, Ying, et al.
Publicado: (2020)

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
por: Zhao, Yizhuo, et al.
Publicado: (2022)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy
por: Tian, Jin, et al.
Publicado: (2023)

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
por: Shi, Jianhua, et al.
Publicado: (2021)

Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study
por: Gao, Lijuan, et al.
Publicado: (2023)

The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions
por: Wang, Jinlin, et al.
Publicado: (2017)

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
por: Han, Baohui, et al.
Publicado: (2018)

Pleural Effusion
por: Gray, Frank D.
Publicado: (1963)

Pleural Effusion
por: Brunton, T. Lauder
Publicado: (1898)

Pleural Effusion
por: Sherding, Robert G., et al.
Publicado: (2006)

Pleural Effusions
Publicado: (1877)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

Diagnostic procedure for idiopathic eosinophilic pleural effusion: a single-center experience
por: Luo, Weizhan, et al.
Publicado: (2020)

Current status of and progress in the treatment of malignant pleural effusion of lung cancer
por: Zhao, Yuhua, et al.
Publicado: (2023)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

Use of Platelet Parameters in the Differential Diagnosis of Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Tuberculous Pleural Effusion
por: Ai, Ling, et al.
Publicado: (2022)

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
por: Xu, Qin, et al.
Publicado: (2022)

VEGF Correlates with Inflammation and Fibrosis in Tuberculous Pleural Effusion
por: Bien, Mauo-Ying, et al.
Publicado: (2015)

The diagnostic utility of pleural markers for tuberculosis pleural effusion
por: Zhang, Man, et al.
Publicado: (2020)

Filarial pleural effusion
por: Gowrinath, K.
Publicado: (2011)

Tuberculous Pleural Effusion
por: Schlesinger, Shira A., et al.
Publicado: (2012)

Filariasis and pleural effusion
por: Wiwanitkit, Somsri, et al.
Publicado: (2013)

Encysted Pleural Effusions
por: Viswanathan, R.
Publicado: (1946)

Cholesterol Pleural Effusion
por: Curran, Thomas M.
Publicado: (1948)

Fœtid Pleural Effusion
por: James, Alexander
Publicado: (1891)

The Treatment of Pleural Effusion
Publicado: (1893)

Cytodiagnosis of Pleural Effusions
por: Gulland, G. Lovell
Publicado: (1902)

Fœtid Pleural Effusion
por: James, Alexander
Publicado: (1891)

The sandwiched pleural effusion
por: Venkatnarayan, Kavitha, et al.
Publicado: (2019)

Myelomatous pleural effusion
por: Escribano Serrat, Silvia, et al.
Publicado: (2022)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Exosomal miRNA-profiling of pleural effusion in lung adenocarcinoma and tuberculosis
por: Zhang, Xuede, et al.
Publicado: (2023)

Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions
por: Wang, Maoshui, et al.
Publicado: (2014)

High-throughput autoantibody analysis in malignant pleural effusion and tuberculosis pleural effusion
por: Yi, Fengshuang, et al.
Publicado: (2019)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p7r3r5nojf9a9f0s648jjd5jjq